Treating infectious diseases by targeting the human glycome
Treating infectious diseases by targeting the human glycome
Pneumagen is developing glycan targeted carbohydrate binding modules (CBMs) as a new universal therapeutic modality for the treatment of respiratory tract infections (RTIs).
Latest news
05 Oct, 2020
Pneumagen’s Neumifil for combating COVID-19 featured in SCRIP’s 10 to watch at BIO-Europe Digital